Exploris Health AG harnesses artificial intelligence to develop precise, non-invasive diagnostic tests that accelerate accurate diagnoses and enhance treatment outcomes in healthcare.

The company specializes in artificial intelligence-based diagnostics and therapy solutions, focusing on cardiovascular diseases. Their flagship product, Cardio Explorer, is a non-invasive AI-based test that reliably detects life-threatening narrowing of the coronary arteries (coronary artery disease) — the leading cause of heart attacks — offering significant safety for both physicians and patients.

Exploris Health offers advanced AI services and solutions, including Data Science & Predictive Modeling platforms that enable rapid analysis of complex data structures and development of innovative applications.

The Cardio Explorer system detects obstructive coronary artery disease with high accuracy — achieving an Area Under the Curve (AUC) of 88% in men and 82% in women — utilizing lab data, blood pressure, and basic vitals. It provides life-saving insights early, affordably, and without radiation or invasive procedures, helping close the gender data gap in cardiology.

They also provide personalized therapy solutions for heart failure, enabling optimized self-treatment and therapy management.

Founded in 2018, Exploris Health AG is a privately held company headquartered in Wallisellen, Zürich, Switzerland, with 11-50 employees.

They partner with leading organizations in the healthcare and technology sectors and have received recognition in innovation, including the InsureNXT Innovation Award.